Amendments for: 172-2018-2019-Q4-920200
Current (Jun 1, 2022)
Agreement: Development of a plant-based candidate combination vaccine for SARS-CoV-2 and seasonal influenza (920200). Jan 1, 2019 - Mar 31, 2023
Description:
Development of a plant-derived candidate universal influenza vaccine ready for clinical development
Expected Results:The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Organization: National Research Council CanadaRecipient: Medicago Inc. (For-profit organization)
Location: Quebec, Quebec, CA G1V 3V9
Type: Contribution
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days. The total amended value is -600,000 dollars.
Federal Riding Name: Louis-Hébert (24044)Program Name: Industrial Research Assistance Program – Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.NAICS Code: 325410
Amendment 02 (Jun 1, 2022)
Agreement: Development of a plant-based candidate combination vaccine for SARS-CoV-2 and seasonal influenza - Mar 31, 2023
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days. The total amended value is -600,000 dollars.
Amendment 01 (Sep 4, 2020)
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 306 days.
Amendment 00
Agreement: Development of a universal influenza vaccine (920200). Jan 1, 2019 - Feb 28, 2022
Description:
Development of a plant-derived candidate universal influenza vaccine ready for clinical development
Expected Results:The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Organization: National Research Council CanadaRecipient: Medicago Inc. (For-profit organization)
Location: Quebec, Quebec, CA G1V 3V9
Type: Contribution
Federal Riding Name: Louis-Hébert (24044)
Program Name: Industrial Research Assistance Program – Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.NAICS Code: 325410